Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Idenix Pharmaceuticals logo — Pioneering advancements in antiviral therapies, focused on c...

Idenix Pharmaceuticals

Pioneering advancements in antiviral therapies, focused on combating hepatitis and HIV, with a strong presence in the U.S. and Europe.

Founded 1998 Post-IPO Equity Total: $155.00M Biotechnology, Health Care

General Information

Company Name Idenix Pharmaceuticals
Founded Year 1998
Founders / Decision Makers
Team member
Industries Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Idenix Pharmaceuticals. To contact Idenix Pharmaceuticals, visit idenix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Idenix Pharmaceuticals compare?

A PDF of Idenix Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Idenix Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Idenix Pharmaceuticals

Idenix Pharmaceuticals is a biopharmaceutical company founded in 1998 that focuses on developing antiviral therapies for diseases such as hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus type I (HIV), and acquired immune deficiency syndrome (AIDS). The company achieved a significant milestone in July 2009 by completing a proof-of-concept clinical trial for treatment-naive HCV genotype I infected patients. Shortly after, in October 2009, Idenix initiated a 14-day dose-ranging phase IIa clinical trial to evaluate IDX184 in combination with pegylated interferon and ribavirin for the same patient group. Additionally, IDX320 was chosen as the lead clinical candidate from its protease inhibitor discovery program. The company's research and development operations are based in the United States and Europe. Their last investment, totaling $107.00M, was received as a Post-IPO equity investment on 28th January 2014 from The Baupost Group. With a strong presence in the U.S. and Europe, Idenix Pharmaceuticals is pioneering advancements in antiviral therapies, cementing its position in the Biotechnology and Health Care industries.

Business keywords: biopharmaceutical company, drug discovery, antiviral therapies, HCV treatment, hepatitis C virus, HBV treatment, HIV treatment, AIDS treatment, clinical trials, drug development, protease inhibitors, proof-of-concept trials, pegylated interferon, ribavirin, viral diseases

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $107.00M 1
The Baupost Group
28 Jan 2014
Post IPO Equity $5.00M -
25 Apr 2011
Post IPO Equity $20.00M 1
ViiV Healthcare
23 Nov 2010
Post IPO Equity $23.00M -
01 Aug 2009
Venture Round Undisclosed 1
Techno Venture Management
01 Jan 2003

Idenix Pharmaceuticals Alternatives & Competitors

View All Alternatives
Idenix Pharmaceuticals vs
Replicor Inc.
Replicor Inc. Canada

292 million people have chronic hepatitis B. We're developing the cure.

6 employees
Biotechnology, Health Care
Idenix Pharmaceuticals vs
Genelabs Technologies
Genelabs Technologies

Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds...

Venture round
24 employees
Biopharma, Biotechnology
Idenix Pharmaceuticals vs
Phenomix
Phenomix

A pioneering biotech company dedicated to developing groundbreaking therapies for diabetes and hepat...

Venture round
Biotechnology, Health Care
View all alternatives

FAQ About Idenix Pharmaceuticals

Pioneering advancements in antiviral therapies, focused on combating hepatitis and HIV, with a strong presence in the U.S. and Europe.
Idenix Pharmaceuticals was founded in 1998.
Idenix Pharmaceuticals operates in Biotechnology and Health Care. Its work centres on biopharmaceutical company, drug discovery, antiviral therapies and HCV treatment.
Idenix Pharmaceuticals has completed 5 funding rounds, raising a total of $155.00M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Idenix Pharmaceuticals include Replicor Inc., Genelabs Technologies, Phenomix, KalVista Pharmaceuticals, Inc., Anadys Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Idenix Pharmaceuticals and Replicor Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Idenix Pharmaceuticals, https://bouncewatch.com/company/idenix-pharmaceuticals, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout